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Abstract
Background: Hydrogen cyanide (HCN) and carbon monoxide (CO) may be important components of smoke from fire 
accidents. Accordingly, patients admitted to hospital from fire accidents may have been exposed to both HCN and CO. 
Cyanide (CN) intoxication results in cytotoxic hypoxia leading to organ dysfunction and possibly death. While several 
reports support the use of hyperbaric oxygen therapy (HBO) for the treatment of severe CO poisoning, limited data 
exist on the effect of HBO during CN poisoning. HBO increases the elimination rate of CO haemoglobin in proportion 
to the increased oxygen partial pressure and animal experiments have shown that in rats exposed to CN intoxication, 
HBO can increase the concentration of CN in whole blood.
Objective: The purpose of the present study was to determine whole blood CN concentrations in fire victims before 
and after HBO treatment.
Materials and methods: The patients included were those admitted to the hospital because of CO intoxication, either 
as fire victims with smoke inhalation injuries or from other exposures to CO. In thirty-seven of these patients we 
measured CN concentrations in blood samples, using a Conway/microdiffusion technique, before and after HBO. The 
blood samples consisted of the remaining 2 mL from the arterial blood gas analysis. CN concentration in blood from 
fire victims was compared to 12 patients from non-fire accidents but otherwise also exposed to CO intoxication.
Results: The mean WB-CN concentration before patients received HBO did not differ significantly between the two 
groups of patients (p = 0.42). The difference between WB-CN before and after HBO did not differ significantly between 
the two groups of patients (p = 0.7). Lactate in plasma before and after did not differ significantly between the two 
groups of patients. Twelve of the 25 fire patients and one of the non-fire patients had been given a dose of 
hydroxycobalamin before HBO.
Discussion and Conclusion: CN concentrations in blood from patients admitted to hospital with CO intoxication and 
smoke inhalation exposure did not differ significantly from controls. Accordingly, we were not able to detect any 
changes in CN concentrations in blood after treatment with HBO.
Trial Registration: ClinicalTrials.gov identifier: NCT00280579
Introduction
Reports have shown that patients admitted to hospital
from fire accidents may have been exposed to cyanide
(CN) gases as well as carbon monoxide (CO) [1-3]. Baud
showed [4] that persons from fire accidents were both
poisoned with CN and CO. CN is a potent intracellular
poison which can be developed from incomplete com-
bustion of materials containing nitrogen in fire accidents
[5]. When fire temperatures reach 315°C (600°F) CN
develops in the form of hydrogen cyanide (HCN) [1]. In
the cell CN binds to the enzyme cytochrome oxidase a, a3
(CCO) (i.e. complex IV in the mitochondrial electron
transport chain) similar to CO [6]; thus stopping the
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Page 2 of 6mitochondrial respiration chain and the formation of
adenosine triphosphate (ATP).
According to several clinical studies, there is general
agreement that HBO treatment is recommended in case
of CO poisoning if the patient suffers from severe neuro-
logical symptoms or has been exposed to COHb concen-
trations higher than 25%. The current treatment
indications for HBO therapy during CO poisoning in
Denmark is in alignment with the recommendations as
stated above [7-10]. Current treatment of CN poisoning
is based on treating basic symptoms combined with
hydroxycobalamin (Cyanokit®, OHCob) given i.v. [11,12].
OHCob i.v. reacts with any CN present in the blood
stream and creates cyanocobalamin (B12 vitamin) a non-
toxic substance that is excreted via the kidneys [13].
Whether OHCob can pass through the vascular wall and
the blood-brain barrier to induce a direct detoxification
effect within the central nervous system remains to be
investigated [14]. However a French study by Astier et al
demonstrated that OHCob may enter the intracellular
compartment under in-vitro conditions [15].
HBO is recommended especially when supportive
measures and other CN antidotes fail [16-18]. HBO is
known to facilitate the dissociation of CO from cyto-
chrome oxidase a, a3 in the mitochondrial respiratory
chain [19].
In an animal model we have previously shown that
HBO has an effect on the concentration of whole-blood
cyanide (WB-CN) which increased significantly in com-
parison to untreated controls when measured 2 hours
after HBO treatment [20]. Accordingly, the primary pur-
pose of this clinical protocol was to measure whether
HBO treatment in the CO and CN exposed patient would
have the same effect on WB-CN in humans as demon-
strated in the animal experiments. The secondary pur-
pose of this clinical protocol was to determine how many
patients from fires were CN poisoned above the toxic
concentration levels defined as a whole-blood concentra-
tion higher than 39 μmol/L [11].
Methods
The Local Ethics Committee approved the study. The
study is registered at ClinicalTrials.gov identifier:
NCT00280579. We studied 25 fire victims, aged 18 years
or older, who were admitted to the level-1 trauma centre
at Copenhagen University Hospital, Rigshospitalet for
treatment of CO poisoning and smoke inhalation injury
between January 2006 and November 2009. Twelve con-
trol subjects (i.e patients from non-fire accidents who
were receiving HBO treatment for other causes such as
suicide attempts or accidental gas inhalation) were also
included.
Time sequence of blood sampling: Immediately before
and after HBO therapy two 2 mL arterial blood samples
were obtained from the patients. One sample was used
immediately to determine the blood lactate concentration
using the Radiometer ABL version 725 (Radiometer A/S,
Copenhagen, Denmark). Any air bubbles were carefully
removed from the other blood sample, and the syringe
was tightly sealed and stored at -25°C until WB-CN con-
centration analysis the next day. Accordingly, WB-CN
concentrations were determined before and after the first
HBO treatment session. Two hours after the first acute
HBO treatment session, a third blood sample for WB-CN
concentration measurement was obtained. As controls
we used blood samples from non-fire patients, collected
and stored in the same way.
Whole blood CN measurements
CN was measured using a Conway/microdiffusion
method, where CN is liberated from blood in a gaseous
phase and subsequently bound to OHCob forming
cyanocobalamin [21]. The Conway chambers (Bel-Art
products, Pequannock, NJ, USA) were placed on a heat-
ing plate and all reactions took place at 45°C. In the outer
ring 1mL blood was mixed with 1 mL of 5% Triton X 100
and 2 mL of 50 μM OHCob in 0.067 M KH 2PO 4 was
placed in the inner ring. Immediately before closing the
chamber, 2 mL of 6.55 M sulphuric acid was added in the
outer ring. In this acidic solution, the CN is in the proto-
nated form, HCN, with a boiling point of 25.6°C. Thus
any CN bound or free from the blood evaporates and
binds to the OHCob in the inner ring and forms cyanoco-
balamin. Accordingly, previously given OHCob should
not interfere with measurements of the cyanide concen-
trations in whole blood [21] After 30 min the solution in
the absorbent chamber was aspirated and absorption at
361 nm was read (Shimadzu UV-1601 spectrophotome-
ter, Shimadzu, Kyoto, Japan). The absorption increased
linearly with the concentration of CN in the blood sample
up to 100 μmol/L. All measurements were performed in
duplicate and each series included a blank and three stan-
dards of 20, 40, and 100 μmol/L in 1 mol/L KOH. The
lower limit of quantification was estimated to 20 μmol/L.
Data analysis and statistics
Descriptive data are presented with mean and standard
error of mean (SEM). Groups were compared with the
Mann-Whitney test using SAS for Windows, version 9.1
(SAS Institute Inc., Cary, USA). P-values for CN concen-
trations are also presented with a quantification limit
adjusted Mann-Whitney test, where all values below 20
μmol/L are analysed as 10 μmol/L.
Results
Effect of CN poisoning on WB-CN during HBO
General patient data
The patients' average age was 52 years. We included 37
patients of whom 19 were male and 18 female. Twenty-
five patients were admitted from fire accidents and 12
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CO poisoning from non-fire accidents. The average time
from accident to arrival at the Trauma Centre was 3.22
hours. The time from arrival at the Trauma Centre to ini-
tiating HBO was 3.7 hours. Neither the time interval
from accident to arrival, nor the time interval from arrival
at the Trauma Centre to HBO treatment were initiated,
showed any significant differences among patient groups.
Patients from fire accidents
Of the 25 patients from fire accidents, 2 had a WB-CN
concentration higher than 39 μmol/L before HBO.
OHCob was given to 12 patients, before HBO treatment,
because of suspected cyanide poisoning.
In blood tests before and after HBO 13 showed an
increase in WB-CN concentration and 10 a decrease. In
the remaining two the WB-CN concentration did not
change.
Of the 25 patients admitted from fire-accidents we
were able to measure WB-CN concentration 2 hours after
HBO therapy in 11 patients. Of these patients 2 had not
received OHCob. No significant increase or decrease was
observed in the 3 rd WB-CN measurement.
The mean WB-CN concentration on arrival for patients
having received OHCob before the blood test was 15.4
μmol/L +/- SEM 4.1 μmol/L. In patients not receiving
OHCob the mean was 14.33 μmol/L +/- SEM 1.4 μmol/L
.The mean difference between CN concentration in blood
before and after HBO in patients receiving OHCob was
2.1 μmol/L +/- SEM 1.4 μmol/L. Patients not receiving
OHCob had a mean of 1.9 μmol/L +/- SEM 1.9 μmol/L.
The mean lactate concentration on arrival for patients
receiving OHCob was 5 mmol/L and for patients not
receiving OHCob 3.7 mmol/L. The mean lactate concen-
tration after HBO was 1.9 mmol/L for patients receiving
OHCob and 1.3 mmol/L for patients not receiving
OHCob. See Table 1.
Patients from non-fire accidents
None of the 12 patients from non-fire accidents had a CN
concentration in whole blood higher than 39 μmol/L
before HBO. OHCob was given to one patient before
leaving the level-1 Trauma Centre thus before HBO. In
blood tests before and after HBO seven patients showed
an increase in WB-CN and five a decrease. Of the 12
patients from non-fire accidents we were able to measure
WB-CN 2 hours after HBO therapy in 3 patients, of these
which only 1 had received OHCob. No significant
increase or decrease was observed in the 3 rd WB-CN
measurement.
The mean WB-CN concentration on arrival was 12.5
μmol/L +/- SEM 1.5 μmol/L. The mean difference
between CN concentration in whole blood before and
after HBO was 1.1 μmol/L +/- SEM 0.6 μmol/L.
The mean lactate concentration on arrival was 4.4
mmol/L. The mean lactate concentration after HBO was
2.5 mmol/L. See Table 1.
Patients from fire accidents compared with patients from 
non-fire accidents
The mean WB-CN concentration on arrival did not differ
significantly between the three groups of patients. See
Table 2. WB-CN concentrations before and after HBO
differ significantly in the three groups of patients. See
Table 2.
Lactate concentrations in plasma before and after HBO
treatments did not differ significantly in the three groups
of patients.
Case stories
We found two CN poisoned patients with WB-CN con-
centrations higher than 39 μmol/L, and include the case
stories to illustrate the course of treatment following fire
accidents with suspected of CO and CN poisoning.
Case 1
In 2007 a fire victim patient was transported from pri-
mary hospital to our level 1 Trauma Centre. The patient
was rescued from a burning apartment where the patient
was lying in a cloud of smoke up to1,5 meters. Arterial
puncture at a primary hospital showed a carboxyhaemo-
globin (COHb) of 40% and lactate of 8,2 mmol/L in com-
bination with alcohol intoxication. During ambulance
transport, the patient shortly regained consciousness, but
was unconscious again on arrival at primary hospital.
Due to possible inhalation injuries of the upper airways,
the patient was sedated with propofol and fentanyl and
intubated at primary hospital before transportation to
Rigshospitalet for subsequent HBO treatment. Blood
tests for CN were taken on the arrival to Rigshospitalet
including a new arterial puncture. This showed pH 7.33,
pCO 2 6.6, pO 2 6.65 , BE 0.2, COHb of 17% and lactate of
4.2 mmol/L. Subsequently, the patient was given OHCob
as CN antidote. The WB-CN concentration before anti-
dote treatment was 58 μmol/l. There were plenty of soot
particles in the tube; accordingly, bronco alveolar lavage
(BAL) was considered, but it was decided that HBO had
first priority. The patient received 3 HBO therapies dur-
ing the first 24 hours. After the first 2 HBO treatments
BAL was performed and showed intact mucous mem-
branes coated with a large amount of soot particles.
COHb normalised after the first HBO therapy to 2.8%
and WB-CN concentration was 28 μmol/l. After 24 hours
the CN level in blood was still high (23 μmol/l) in spite of
OHCob. During the hospitalisation the patient received 5
HBO treatments. The patient was extubated 5 days later
without problems and transferred to the neurological
unit.
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An unconscious patient was rescued from a burning
apartment with a Glasgow Coma Scale 3. The patient was
intubated and brought to the level 1 Trauma Centre.
Blood tests for CN were taken on the arrival including an
arterial puncture for blood gas analysis. The arterial
blood sample showed a COHb of 33.5% and lactate of 9.0
mmol/L. After the blood tests the patient received
OHCob. The patient had 2 nd and 3 rd degree burns on
17% of the body, arms and face. A BAL performed in the
Trauma Centre showed soot particles coating of the
mucous membranes in the trachea and major bronchi.
The patient was sent to the hyperbaric chamber for HBO
treatment. Immediately before HBO a blood sample was
taken that showed pH 7.32, pCO 2 5.65, pO 2 23.5 , BE -
3.7, COHb of 10.2% and plasma-lactate of 4 mmol/L. The
patient received 2 HBO treatments before being admitted
to the Intensive care unit. After the first HBO treatment
the arterial puncture showed pH 7.3, pCO 2 6.23, pO 2
11.8 , BE -3.6, COHb of 3.5% and plasma-lactate of 2.8
mmol/L. The WB-CN concentration was 39 μmol/l
before and 14 μmol/l after the first HBO treatment. Two
hours after HBO the WB-CN concentration was 13
μmol/l. During the next 5 days the patient developed sep-
tic shock followed by multiple organ dysfunction syn-
drome caused by the severe burn injuries. On the 5 th day
the patient developed hyperthermia, which was compli-
cated by cardiovascular collapse and a fatal irreversible
circulatory arrest.
Discussion
In CN poisoning the toxic concentration in blood has
been reported to be 39 μmol/L and higher than 100
μmol/L is potentially lethal [11]. In the group of patients
from fire accidents only 2 patients had a WB-CN concen-
tration higher than 39 μmol/L and 1 of those received
OHCob before the blood test. In the group of non-fire
patients none had a CN concentration higher than 39
Table 1: Mean WB-CN, lactate and average COHgb















Patients from fires 
receiving OHCob
N = 12
15.4 μmol/L 2.1 μmol/L 5 mmol/L 1.9 mmol/L 27.9% 2%
Patients from fires not 
receiving OHCob
N = 13
14.33 μmol/L 1.9 μmol/L 3.7 mmol/L 1.3 mmol/L 23% 1.9%
Patients from non-fires
N = 12
12.5 μmol/L 1.1 μmol/L 4.4 mmol/L 2.5 mmol/L 25.9% 2.9%
Mean WB-CN, lactate and carbon monoxide concentrations before and after HBO therapy in all three groups. N = number of patients.
Table 2: Comparison of WB-CN
Patients from fires receiving OHCob Patients from fires not receiving OHCob
N = 12 N = 13
WB-CN at arrival Differences in WB-CN 
before and after HBO
WB-CN at arrival Differences in WB-CN 
before and after HBO
Patients from fires not 
receiving OHCob
P = 0.72 P = 0.07
N = 13
Patients from non-fires P = 0.4 P = 0.16 P = 0.48 P = 0.7
N = 12
When comparing WB-CN concentration on arrival at the Trauma Centre or WB-CN concentration before and after HBO amongst all three 
groups there are no significant differences. P = p-values. N = number of patients.
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patients were transferred to the level-1 Trauma Centre
from other hospitals before HBO and consequently, the
WB-CN blood tests were taken hours after the patients
had been exposed to CN. Following absorption CN is
rapidly distributed throughout the body. Because of the
time delay from possible CN exposure until blood sam-
pling, most of the CN would have distributed to the tis-
sues before the blood sample was taken. Therefore, it
cannot be excluded that some of the patients who were
exposed to fire have had higher concentrations of CN in
their blood, than we were able to measure. We therefore
recommend, if possible, taking the WB-CN test at the
scene of the emergency.
In an earlier study at Rigshospitalet the result was simi-
lar, showing that only 2 of 40 patients had a CN concen-
tration higher than 39 μmol/L even though a greater
number of patients were expected to have CN poisoning
[22]. The study by Meyhoff et al. [22], included two con-
trol groups of which one was consisting of smokers and
the other non-smokers. Their results showed that WB-
CN concentrations were marginally higher in smokers
compared with non-smokers and that there were no sta-
tistical differences between these groups. Accordingly,
there does not seem to be any effect of smoking on CN
levels on whole-blood measurements. Based on these
observations, the current study did not evaluate or regis-
ter whether or not patients admitted with severe CO-poi-
soning were smokers.
The Conway method does not show how much CN is
stored in the tissues. It has been demonstrated, that once
CN is absorbed, the body will distribute it with 50% pres-
ent in blood, 25% in muscle and 25% in other of the
organs, predominantly in the liver and brain [23]. This
also applies to other available methods currently used for
measuring CN concentrations. There is a major need for
a new method of measuring CN. Because of rapid redis-
tribution, the measured WB-CN concentration is likely to
be too low.
Before HBO the WB-CN concentration in fire victims
did not differ significantly from patients not exposed to
fire or smoke inhalation. One explanation may be that the
fire victims in the present study were not CN poisoned.
This does not corresponds with earlier studies [1-4].
Another possible explanation for this observation may be
found in the delay from the time of CN exposure and
HBO treatment. The CN half-life in whole blood is only 1
hour [21]. Consequently, CN may be irreversibly stored in
the cells by the time the patients receive HBO. This may
seem at variance with the findings of Lawson-Smith et al.
[20], where WB-CN concentrations measured in rats
exposed to CN poisoning, were found to increase after
HBO therapy [20]. However, in the Lawson-Smith et al.
study [20], rats were exposed to significantly higher doses
of cyanide and received HBO closer to the CN exposure
as compared to the patients in this report. We were not
able to detect any differences in WB-CN concentrations
before and after HBO. Nor did the WB-CN concentra-
tions differ significantly in the two groups. This does not
mean that HBO treatment will not be of benefit for the
patient suffering from tissue hypoxia caused by CN poi-
soning, but rather that the WB-CN concentration in our
patients were too low to detect any differences before and
after HBO therapy. In our relatively small sample, we
were not able to produce a correlation between WB-CN
concentrations and plasma lactate concentrations. (See
Table 1) as previously demonstrated by Baud et al. [24].
Nevertheless HBO did cause a substantial reduction in
plasma lactate and COHb (See Table 1).
Clinicians are often unable to diagnose cyanide poison-
ing in the emergency setting [25] and it is often difficult
to find the patients with a WB-CN concentration higher
than 39 μmol/L [11]. Clinicians often treat patients with
OHCob because of the history of fire accident. As men-
tioned above, OHCob converts CN to a non-toxic sub-
stance being cyanocobalamin (B12-vitamin).
Cyanocobalamin is excreted through the kidneys [13] and
has a safe side effect profile making it safe to infuse even
without a clear diagnose of CN poisoning. Side effects are
red colouring of skin and urine, urticarial eczema and sel-
dom anaphylactic chock is seen [14]. Williams et al found
that OHCob accelerates the renal excretion of CN when
CN was administered as NaCN [26]. Whether this is the
case following HCN intoxication from fire accidents
remains unknown.
In patients hospitalized with a history of fire accident,
combined with severe neurological symptoms such as
reduced Glasgow Coma Scale Scoring and either soot
particles in the mouth or tracheal expectoration, is likely
to be indicative of CN poisoning [11]. In this report, a
majority of patients from fire accidents received OHCob
as apposed to 1 patient from non-fire accidents. In keep-
ing with the apparently safe side effect profile of OHCob
and the damage CN poisoning may cause if left untreated,
we recommend the use of OHCob infusion even if the
WB-CN concentration has not been confirmed by direct
measurement. Reports have shown that survivors of CN
poisoning may have permanent sequelae in form of brain
damage. CN is recognized as a cause of permanent neu-
rological disability, ranging from various extrapyramidal
syndromes to post-anoxic vegetative states [27]. This has
been shown by high-resolution magnetic resonance
imaging and positron emission tomography [28]. The
area is not well investigated and will require more studies
in the future.
Of the 25 patients admitted to the hospital from fire
accidents, at least 2 patients were exposed to toxic levels
of CN. In view of the limitations with respect to the time
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measurements, we conclude that patients exposed to fire
accidents may well suffer from CN intoxication. Accord-
ingly, they should be treated with a suitable antidote even
in the absence of verified blood CN measurements and
preferably in combination with HBO treatment, the latter
being the primary treatment if combined with CO poi-
soning.
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